Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease

Trial Profile

A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osilodrostat (Primary)
  • Indications Pituitary ACTH hypersecretion
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LINC-1; LINC-2
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 18 Jun 2023 Results (n=229) of a pooled analysis assessing how dosing, including dose uptitration and adjustments during long-term maintenance, can provide rapid, sustained mUFC control, minimize AEs and improve treatment outcomes from LINC program trials (LINC 2, 3 and 4) presented at the 105th Annual Meeting of the Endocrine Society
  • 23 Mar 2021 Results (n=19) reporting long-term efficacy and safety results of LINC 2 study following an optional extension (n=16) presented at the 103rd Annual Meeting of the Endocrine Society
  • 16 Dec 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top